Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Li, Da ^a   Bi, Fang Fang ^a   Cao, Ji Min ^b   Cao, Chen ^c   Li, Chun Yan ^b   Yang, Qing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

BRCA1; BRCA2; Epidermal growth factor receptor; Ovarian cancer

Indexed keywords

BISULFITE; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LENTIVIRUS VECTOR;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

BRCA1 PROTEIN; BRCA2 PROTEIN; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENES, BRCA1; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84889811752     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-102     Document Type: Article

References (20)

1. Therapeutic strategies in epithelial ovarian cancer. Kim A, Ueda Y, Naka T, Enomoto T, J Exp Clin Cancer Res 2012 31 14 10.1186/1756-9966-31-14 22330607
2. IGF-1 and BRCA1 signalling pathways in familial cancer. Werner H, Bruchim I, Lancet Oncol 2012 13 537 e544 10.1016/S1470-2045(12)70362-5 23182194
3. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Gui T, Shen K, Cancer Epidemiol 2012 36 490 496 10.1016/j.canep.2012.06.005 22818908
4. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Sheng Q, Liu J, Br J Cancer 2011 104 1241 1245 10.1038/bjc.2011.62 21364581
5. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A, Oncogene 2012 31 4139 4149 10.1038/onc.2011.572 22158046
6. Implications of EGFR inhibition in ovarian cancer cell proliferation. Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS, Gynecol Oncol 2008 109 411 417 10.1016/j.ygyno.2008.02.030 18423824
7. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G, Levine B, Cell 2013 154 1269 1284 10.1016/j.cell.2013.08.015 24034250
8. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T, Cancer Epidemiol Biomarkers Prev 2013 22 2110 2115 10.1158/1055-9965.EPI-13-0193 23966579
9. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. Nowsheen S, Cooper T, Stanley JA, Yang ES, PLoS One 2012 7 46614 10.1371/journal.pone.0046614 23071597
10. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM, Cancer Res 2009 69 1273 1278 10.1158/0008-5472.CAN-08-2954 19190334
11. Promoter hypomethylation, especially around the E26 transformation- specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. Bi FF, Li D, Yang Q, BMC Cancer 2013 13 90 10.1186/1471-2407-13-90 23442605
12. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR, Mol Cancer Ther 2006 5 382 390 10.1158/1535-7163.MCT-05-0303 16505113
13. Dynamic DNA methylation across diverse human cell lines and tissues. Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F, Cross MK, Williams BA, Stamatoyannopoulos JA, Crawford GE, Absher DM, Wold BJ, Myers RM, Genome Res 2013 23 555 567 10.1101/gr.147942.112 23325432
14. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Burga LN, Hu H, Juvekar A, Tung NM, Troyan SL, Hofstatter EW, Wulf GM, Breast Cancer Res 2011 13 30 10.1186/bcr2850 21396117
15. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Samani AA, Yakar S, LeRoith D, Brodt P, Endocr Rev 2007 28 20 47 16931767 (Pubitemid 46220849)
16. BRCA1-Dependent Translational Regulation in Breast Cancer Cells. Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND, PLoS One 2013 8 67313 10.1371/journal.pone.0067313 23805307
17. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Calvo V, Beato M, Cancer Res 2011 71 3422 3431 10.1158/0008-5472.CAN-10-3670 21531767
18. Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM, Mol Endocrinol 2009 23 1135 1146 10.1210/me.2008-0347 19389812
19. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG, Tomita YA, Rosen EM, Mol Endocrinol 2010 24 76 90 10.1210/me.2009-0218 19887647
20. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, Werner H, Cancer Lett 2007 257 236 243 10.1016/j.canlet.2007.07.019 17766039 (Pubitemid 47538827)